Cediranib
Metastatic Urothelial Carcinoma
M.D. Anderson Cancer CenterSmall moleculePhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Metastatic Urothelial Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Vasgene Therapeutics, Inc | Phase 2/3 | BB |
Irinotecan Pfizer | Phase 3 | BB |
(+)-VINCRISTINE Pfizer | Phase 3 | BB |
Durvalumab Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Olaparib Rahul Aggarwal | Phase 2 | BB |
View all 21 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →